硼替佐米联合地塞米松、来那度胺化疗方案治疗多发性骨髓瘤的疗效和安全性评价  

Efficacy and Safety Evaluation of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen in the Treatment of Multiple Myeloma

作　　者：毛沛沛[1] 杨琛[1] MAO Peipei;YANG Chen(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2023年第3期502-506,共5页The Practical Journal of Cancer

摘　　要：目的 探讨硼替佐米联合地塞米松、来那度胺化疗方案治疗多发性骨髓瘤的疗效及安全性。方法 将多发性骨髓瘤患者96例按随机数字表法分为观察组和对照组。对照组采用硼替佐米联合环磷酰胺、地塞米松化疗方案,观察组采用硼替佐米联合地塞米松、来那度胺化疗方案,均连续给予3个疗程的治疗(28 d为1个疗程)。将2组患者的各项指标进行统一的对比分析。结果 治疗后观察组患者的临床总有效率(93.75%)高于对照组(79.17%);治疗后2组患者的血清白细胞介素(IL)-6、IL-17、C反应蛋白(CRP)、M蛋白、β2微球蛋白水平、骨髓瘤细胞比例、外周血CD3^(+)CD8^(+)水平与治疗前比较均降低,观察组较对照组均处于较低水平;治疗后2组患者外周血CD3^(+)CD4^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+)、Treg、血清血红蛋白(Hb)水平与治疗前比较均升高,观察组较对照组均处于较高水平,有显著性差异(P均<0.05);治疗期间2组不良反应总发生率比较无显著性差异(P>0.05)。结论 多发性骨髓瘤患者采用硼替佐米联合地塞米松、来那度胺化疗方案治疗,能够减轻机体炎症反应,调节免疫功能,疗效显著,且整体安全性较高。Objective To investigate the effect and safety of bortezomib combined with dexamethasone and lenalidomide chemotherapy regimen on the immune function and inflammatory response of patients with multiple myeloma.Methods 96 patients with multiple myeloma were divided into the observation group and the control group, with 48 cases in each group.The control group was given bortezomib combined with cyclophosphamide and dexamethasone chemotherapy, and the observation group was given bortezomib combined with dexamethasone and lenalidomide chemotherapy.Both groups received 3 consecutive courses of treatment(28 d was a course of treatment).The indicators of the 2 groups(the clinical effects after treatment, serum Interleukin(IL)-6,IL-17,C-reactive protein(CRP) levels, immune function, M protein, Hemoglobin(Hb),β2 microglobulin levels, myeloma cell ratio before and after treatment and adverse reactions during treatment) were compared and analyzed.Results After treatment, the total clinical effective rate(93.75%) of the observation group was higher than that of the control group(79.17%);Compared with before treatment, the levels of serum IL-6,IL-17,CRP,M protein, β2 microglobulin, the proportion of myeloma cells, and the CD3^(+)CD8^(+)levels in peripheral blood of the 2 groups of patients decreased after treatment, and the observation group was lower than the control group.After treatment, the levels of peripheral blood CD3^(+)CD4^(+),CD3^(+)CD4^(+)/CD3^(+)CD8^(+),Treg, and serum Hb in the 2 groups all increased, and the observation group was at a higher level than the control group, and there was a statistically significant difference in the data(all P<0.05);There was no significant difference in the total incidence of adverse reactions between the 2 groups during the treatment period.(P>0.05).Conclusion The chemotherapy regimen of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma patients can reduce the body’s inflammatory response and regulate immune function, with significan

关 键 词：多发性骨髓瘤 硼替佐米 地塞米松 来那度胺 免疫功能 炎症反应 安全性 

分 类 号：R733.3[医药卫生—肿瘤]